ClinicalTrials.Veeva

Menu

Cognitive Disorders in Hereditary Spastic Paraplegia Type 4 (SPG-TEP)

C

Central Hospital, Nancy, France

Status

Enrolling

Conditions

Spastic Paraplegia

Treatments

Radiation: 18-FDG-PET

Study type

Observational

Funder types

Other

Identifiers

NCT06260982
2021PI148

Details and patient eligibility

About

Hereditary spastic paraplegia type 4 is the most frequent mutation of hereditary spastic paraplegias. It is commonly described as pure, with progressive weakness of the lower limbs, pyramidal syndrome and vesico-sphincter disorders. However, cognitive disorders have been reported for over 20 years, but remain poorly characterized.

Full description

Our primary objective is to describe a pattern of cognitive impairment in Hereditary Spastic Paraplegia type 4 using 18-FDG-PET metabolic imaging.

As secondary objectives, we wish to study the presence of correlations between neuropsychological tests, clinical examination, 18-FDG-PET data and general and genetic data of the pathology. We also wish to investigate correlations between genotype and phenotype.

Enrollment

30 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient over 18 years of age, living in the Grand Est region (France)
  • Patient with a pathogenic or probably pathogenic variant (class 4 or 5) in the SPAST gene.

Exclusion criteria

  • dementia comorbidities or cognitive disorders unrelated to the pathology that may affect neuropsychological tests.

Trial contacts and locations

1

Loading...

Central trial contact

Mathilde Renaud

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems